Skip to content
This year has brought two cardiology headlines that, at first glance, seem to pull in opposite directions. Earlier in 2026, the American College of Cardiology and American Heart Association released new dyslipidemia guidelines recommending that every adult have their Lp(a) — lipoprotein(a) — checked at least once in their lifetime. Then, just this month, one of the most closely watched Lp(a)-lowering drugs in development, pelacarsen, reported that while it successfully lowered patients’ Lp(a) levels in a large Phase 3 trial, it did not reduce their rate of heart attacks and strokes.
Put those two stories side by side, and you might wonder why the test still matters if the treatment fell short. Here is why we see this as good news: it is precision medicine working exactly as it should — carefully, honestly, and ultimately in your favor.
A Genetic Risk Factor Worth Knowing — Once
Lp(a) is a cholesterol particle whose levels are set almost entirely by your genes rather than by diet, exercise, or lifestyle. Roughly one in five people carry an elevated Lp(a), often without any idea, and it can raise cardiovascular risk independent of standard cholesterol numbers like LDL. Because it is genetically determined, your Lp(a) level stays essentially stable throughout adulthood — which is exactly why the new guidelines call for checking it just once, not with every annual physical. It is a single blood draw, reported in nmol/L, with levels above 125 nmol/L flagging meaningfully increased risk and levels above 250 nmol/L associated with roughly double the typical cardiovascular risk.
The same guideline update also gave a bigger role to apolipoprotein B, or ApoB — a marker that reflects the total number of artery-affecting particles in your blood, not just their cholesterol content. ApoB is now considered especially useful for refining risk in people who already have cardiovascular disease or who fall into a borderline risk category. Together with a new, more individualized risk calculator and more precise LDL cholesterol targets, this update represents the most significant rethinking of preventive lipid care in nearly a decade — and it puts more usable information directly in your hands.
What the Pelacarsen News Actually Tells Us
That brings us to this month’s headline. Pelacarsen — an investigational therapy designed specifically to lower Lp(a) — was tested in Lp(a)HORIZON, a rigorous trial of more than 8,300 people with elevated Lp(a) and existing cardiovascular disease. The drug did exactly what it was designed to do: it lowered Lp(a) levels substantially. But when researchers looked at real patient outcomes — heart attacks, strokes, and urgent procedures — there was not a meaningful difference compared with placebo. Novartis, the drug’s maker, was candid about it, stating that while these were not the results they had hoped for, the trial “provides important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes.”
We share that outlook. A single trial result is a data point, not a verdict on an entire field of research. Several other Lp(a)-lowering therapies, including olpasiran, remain in active development in their own large outcomes trials. Each result — positive or not — sharpens our understanding of exactly how, and for whom, lowering Lp(a) translates into fewer heart attacks and strokes.
Why Testing Still Empowers You Today
Here is the part that matters most for you: none of this changes the value of knowing your own numbers — if anything, it reinforces it. Even without a dedicated Lp(a)-lowering drug on the market yet, an elevated result is genuinely useful information right now. It tells you and your physician that you may benefit from being more assertive about the risk factors we already know how to manage well: getting ApoB and LDL cholesterol to goal with proven therapies, tightening blood pressure control, and looking directly at your arteries rather than relying on risk formulas alone.
This is where advanced imaging earns its place in precision preventive cardiology. A coronary CT angiogram (CCTA) does not estimate your risk from a formula — it shows whether plaque has actually begun forming in your coronary arteries. Paired with a genetic marker like Lp(a) and a refined biomarker like ApoB, CCTA lets us build a plan around your arteries, your biology, and your goals, often years before symptoms would prompt a conversation in a traditional office visit.
Key Takeaways
- The new 2026 ACC/AHA guidelines recommend a one-time Lp(a) blood test for every adult — because it is genetically set, one result lasts a lifetime.
- ApoB testing and the new PREVENT risk calculator add further precision to your personal cardiovascular risk picture.
- The pelacarsen trial lowered Lp(a) but did not reduce heart attacks or strokes — an important, honest data point, not the end of the story. Other Lp(a)-targeted therapies remain in active trials.
- Knowing your numbers now lets us act today, combining proven therapies with advanced imaging like CCTA, rather than waiting on a future pill.
Looking Ahead
That is the real promise of precision cardiology: not a single pill that solves everything, but a continuously improving picture — better tests, smarter imaging, and an expanding menu of therapies — that lets us act early and specifically, on your behalf. If you have not yet had your Lp(a) checked, it is a simple, one-time addition to your next visit with us, and one more piece of the fuller picture we use to help you stay ahead of heart disease rather than react to it.
To learn more about Lp(a) and ApoB testing, or to schedule a coronary CT angiogram, contact Impact Health NY — concierge, precision preventive cardiology in White Plains, NY.